SK Biopharm has created a new drug development task force (TF) with SK Corporation.
This article is translated by AI company Flitto and Alhpa Biz neural machine translation technology
김지선
stockmk2020@alphabiz.co.kr | 2023-03-27 03:15:25
[Alpha Biz=(Chicago) Reporter Kim Jisun] SK biopharmaceuticals has created a new drug development task force (TF) with SK Corporation, the holding company of SK Group.
With a large number of key figures from SK and SK Biopharm in the TF, Choi Yoon-jung, head of SK biopharmaceuticals' strategic investment team, the eldest daughter of SK Group Chairman Choi Tae-won, reportedly joined the group.
According to the industry on the 24th, the two companies have recently set up such a TF to strengthen the development of new drugs in the pharmaceutical and bio sectors. However, as it is still in the early stages of TF formation, no specific development direction has been decided.
While SK CEO and Vice Chairman Jang Dong-hyun headed the TF, SK joined Kim Yeon-tae, head of the bio-investment center, and Cho Ah-ryeon, head of the bio-investment center group, while Lee Dong-hoon and Yoo Chang-ho, head of the strategic and investment division, joined SK biopharmaceuticals. On top of that, Choi's eldest daughter, Choi, is also known to participate.
TF plans to start work on the 27th.
[ⓒ AlphaBIZ. 무단전재-재배포 금지]
많이 본 기사
- 1NH Investment & Securities Cuts NAVER Target Price to KRW 320,000, Maintains ‘Buy’ on AI Growth Outlook
- 2Korean Air and LCC Affiliates Enter Emergency Management as Fuel Costs Surge Amid Middle East Conflict
- 3Lotte Group to Launch KRW 50 Trillion Real Estate Development Push to Tackle Liquidity Pressures
- 4Amazon Web Services to Invest KRW 7 Trillion More in Korea by 2031, Expanding AI Infrastructure
- 5Daesang Executive Arrested in KRW 10 Trillion Sweetener Price-Fixing Probe; CEOs Avoid Detention
- 6China Vanke Posts Record Loss as Property Slump Deepens Financial Strain